Janux Therapeutics (JANX) Income from Continuing Operations: 2020-2025
Historic Income from Continuing Operations for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Income from Continuing Operations rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
- Janux Therapeutics' Income from Continuing Operations amounted to -$24.3 million in Q3 2025, which was up 28.19% from -$33.9 million recorded in Q2 2025.
- Over the past 5 years, Janux Therapeutics' Income from Continuing Operations peaked at -$2.3 million during Q1 2021, and registered a low of -$33.9 million during Q2 2025.
- Over the past 3 years, Janux Therapeutics' median Income from Continuing Operations value was -$17.5 million (recorded in 2023), while the average stood at -$19.0 million.
- Per our database at Business Quant, Janux Therapeutics' Income from Continuing Operations tumbled by 757.17% in 2021 and then skyrocketed by 65.96% in 2024.
- Over the past 5 years, Janux Therapeutics' Income from Continuing Operations (Quarterly) stood at -$13.4 million in 2021, then declined by 19.75% to -$16.1 million in 2022, then climbed by 26.81% to -$11.8 million in 2023, then crashed by 71.93% to -$20.2 million in 2024, then increased by 13.35% to -$24.3 million in 2025.
- Its Income from Continuing Operations was -$24.3 million in Q3 2025, compared to -$33.9 million in Q2 2025 and -$23.5 million in Q1 2025.